ArticleClinical epigenetics2026
The role of epigenetic age acceleration and social disadvantage in cardiometabolic health in southeast Louisiana women.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCardiometabolic risk factors can disrupt DNA methylation (DNAm) patterns, accelerate cellular aging, and contribute to age-related disorders, including cardiovascular disease (CVD) and diabetes. Social disadvantage may exacerbate these biological processes, yet its relationship with epigenetic aging and cardiometabolic disease across time remains incompletely understood. We examined associations between epigenetic age acceleration and both social disadvantage and cardiometabolic diseases. We assessed whether these associations differed in each study wave.
resultsParticipants were drawn from The Women and Their Children's Health (WaTCH) cohort and assessed at Wave 1 (2012-2014; N = 865) and Wave 3 (2023-2025; N = 348). At Wave 1, participants had a mean age of 46.9 ± 11.9 years and identified as Black (38.0%) or White (56.2%). Social disadvantage was assessed using an individual-level socioeconomic status (SES) index (education, income, and health insurance) and the Area Deprivation Index (ADI). DNAm was measured from blood samples to derive epigenetic age acceleration metrics (GrimAge2, PhenoAge, and DunedinPACE). Lower SES index and higher ADI were associated with greater epigenetic age acceleration and a faster pace of aging. CVD (45.2%) and diabetes (15.6%) at Wave 1 were more prevalent among participants with lower SES index, higher ADI, Black race, and higher body mass index (BMI). After adjustment for BMI, alcohol use, ADI, SES, smoking, and cell composition, both CVD and diabetes were associated with higher GrimAge2 and PhenoAge acceleration and a faster pace of aging at Wave 1. At Wave 3, diabetes was associated with all measures of epigenetic age acceleration after covariate adjustment.
conclusionsCVD and diabetes were more common among socially disadvantaged women and were associated with accelerated epigenetic aging. These findings highlight the biological correlates of social disadvantage and underscore the need for targeted public health interventions addressing social drivers of health to mitigate cardiometabolic disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.